BERSV WINTER WISE

There are some important facts to know about RSV this winter season.

Respiratory syncytial virus (RSV) is one of several respiratory viruses that can be serious.

RSV, influenza (flu), COVID-19 can affect anyone, anywhere, anytime.1

Older adults

with any of these may end up in hospital with severe illness²⁻⁶



RSV peaks in autumn and winter but infections can occur

all year round^{1,7,8}



2024 reported cases in older Australians (60 years and over):1

RSV 32,156 56,561

Australia

started to officially record RSV infections in 20219

Estimating the real numbers and impact is only just beginning.3,10

RSV can be as bad as flu:

For older adults, RSV and flu carry a similar risk of ending up in hospital*11



Although often mild, 12,13 RSV can lead to pneumonia in older adults 4,12



Older adults with existing illness have a higher risk of going to hospital with RSV compared with those without;^{†14}

COPD



9.7x higher

Asthma



8.2x higher

Congestive heart failure



4.6x higher

Diabetes



1.7x higher

Older adults with RSV:



Can spend on average

6 days

in hospital^{‡3}

After being in hospital with RSV:



Older adults may have longterm health complications,

need increased care and feel a loss of independence^{15,16}

- * Systematic review with meta-analysis of 16 observational studies: no significant difference between RSV and influenza in hospitalisation and mortality risks in older adults.
- † Retrospective analysis of an acute respiratory infection surveillance project conducted from 2012–15 in two public hospitals in Auckland, New Zealand in adults 18–80 years with selected chronic medical conditions (n=281).14
- † Retrospective review of National Hospital Morbidity Database data for all RSV-associated hospitalisations in Australia over a ten-year period from 2006–2015. Median hospital length of stay, RSV code as principal diagnosis, adults ≥65 years (n=1742) 6 days (IQR 4–9 days).³

RSV can be serious for adults, not just young children:

Compared with children under 5 years, older adults can experience:



hospital stays*3



For older adults:

Immunity tends to weaken with age

making it harder to fight



The chances of ending up in hospital with RSV

increase with age^{2,3,19}



Retrospective review of National Hospital Morbidity Database data for all RSV-associated hospitalisations in Australia over a ten-year period from 2006-2015. Median hospital length of stay, RSV code as principal diagnosis: ≥65 years (n=1742) 6 days (IQR 4-9 days); <5 years (n=60,551) 3 days (IQR 1-4 days). RSV code as principal diagnosis: ≥65 years 59% deaths (82/138) and 4.71% of RSV admissions (82/1742); <5 years 15% deaths (21/138) and 0.03% of RSV admissions (21/60,551); p values not reported.3

Don't wait - Be RSV Winter Wise.



RSV survives on hard surfaces for up to 6 hours¹²

and is easily spread between people, including family members of all ages^{12,21,22}



Common mild symptoms are similar to other respiratory viruses:12,23,24











Cough

Headache

Tiredness

Runny nose

Congestion



Most people are contagious for up to 10 days but some people with ongoing symptoms or serious illness may be contagious for longer^{25,26}



Australians need to know about their RSV risk ahead of autumn and winter.

Speak to your doctor or pharmacist for more information today.

References:

1. Australian Government Department of Health and Aged Care. National notifiable disease surveillance system [updated 2025 Apr 3; accessed 2025 Apr 3]. Available from: nindss.health.gov.au/pbi dashboard 2. Branche AR et al. Clin Infect Dis 2022;74(6):1004-11. 3. Saravanos GL et al. Med J Aust 2019;210(10):447-53. 4. Tseng HF et al. J Infect Dis 2020;222(8):1298-1310. 5. Liu B et al. BMC Infect Dis 2021;21(1):685. 6. Moa AM et al. Influenza Other Respir Viruses 2022;16(1):132-41. 7. Di Giallonardo F et al. Viruses 2018;10(9):476. 8. Obando-Pacheco P et al. J Infect Dis 2018;217(9):1356-64. 9. Australasian College for Infection Prevention and Control. Respiratory syncytial virus [accessed 2025 Apr 3]. Available from: www.acipc.org.au respiratory-syncytial-virus 10. Nazareno AL et al. Influenza Other Respir Viruses 2022;16(6):1082-90. 11. Maggi S et al. Vaccines (Basel) 2022;10(12):2092. 12. Kaler J et al. Cureus 2023;15(3):e36342. 13. Korsten K et al. Eur Respir J 2021;57(4):2002688. 14. Prasad N et al. Clin Infect Dis 2021;73(1):e158-63. 15. Branche AR et al. Influenza Other Respir Viruses 2022;16(6):1151-60. 16. Ubamadu E et al. Infect Dis Ther 2024;13(7):1399-1417. 17. Ascough S et al. Lancet Healthy Longev 2022;3(6):e405-16. 18. Watson A et al. Ther Adv Respir Dis 2021;15: 1753466621995050. 19. US Centers for Disease Control and Prevention (CDC). RSV-NET interactive dashboard [updated 2025 Jan 9; accessed 2025 Jan 15]. Available from: www.cdc.gov/rsv/php/surveillance/rsv-net.html 20. IQVIA. Market research prepared for GSK, June 2023, REF-235404. 21. Reis J et al. PLoS Comput Biol 2016;12(10):e1005133. 22. Otomaru H et al. Am J Epidemiol 2021;190:2536-43. 23. Kodama F et al. Infect Dis Clin North Am 2017;31:767-90. 24. Australian Centre for Disease Control. COVID-19 [updated 2025 Jan 29]. Available from: www.cdc.gov.au/topics/respiratory-syncytial-virus-rsv 26. Better Health Channel. Respiratory syncytial virus (RSV) [updated 2025 Jan 7; accessed 2025 Jan 29]. Available from: www.betterhealth.vic.gov.au/respi